




fect, with all substituents equatorially disposed. Altogether, there are some 19 stereocentres embedded within this elaborate macrolactone core, along with two hydroxyl-bearing stereocentres in the (*Z,E*)-1,4-diene side chain appended to C<sub>37</sub>.

At this early stage in the structural elucidation of spirastrellolide, only a partial stereochemical assignment was available,<sup>5</sup> where the relationship between three stereocentres (C<sub>1</sub>–C<sub>7</sub>, C<sub>9</sub>–C<sub>24</sub> and C<sub>27</sub>–C<sub>38</sub>) was unknown. In view of this ambiguity, our initial synthetic efforts towards spirastrellolide focussed on constructing the C<sub>1</sub>–C<sub>21</sub> southern hemisphere segment **2**, containing both the [6,6]-spiroacetal and a candidate *trans*-disubstituted tetrahydropyran, as reported herein.

Our retrosynthesis of the C<sub>1</sub>–C<sub>21</sub> segment **2** of spirastrellolide, as outlined in Scheme 1, is based on the planned coupling of three key subunits **3**, **4** and **5**. We envisaged that a suitable open-chain precursor **6** to the required [6,6]-spiroacetal **2** might be derived from the coupling of




**Scheme 2** Asymmetric synthesis of the three key subunits **3**, **4** and **5**.

alkyne **7** with aldehyde **3**. Recognition of a 1,5-*anti* relationship between C<sub>9</sub> and C<sub>13</sub> guided our choice of a strategic C<sub>9</sub>–C<sub>10</sub> bond disconnection to reveal the methyl ketone **4**, containing a masked alkyne functionality, and the A-ring aldehyde **5**. Following precedent set by ourselves<sup>6</sup> and the Evans group,<sup>7</sup> a boron-mediated aldol coupling<sup>8</sup> between **4** and **5** was anticipated to install the desired C<sub>9</sub> configuration relative to the inducing C<sub>13</sub> stereocentre. A subsequent hydroxyl-directed 1,3-*anti* reduction should then generate the required C<sub>11</sub> stereocentre.


As shown in Scheme 2, the synthesis of the C<sub>10</sub>–C<sub>16</sub> subunit **4** commenced from our lactate-derived ketone **8**<sup>9</sup> and the aldehyde **9** (prepared from glyoxal<sup>10</sup>). An *anti* aldol addition of the kinetically generated (*E*)-boron enolate (*c*-Hex<sub>2</sub>BCl, Me<sub>2</sub>NEt) with a solution of freshly prepared aldehyde **9** gave the expected  $\beta$ -hydroxy ketone **10**,<sup>11,12</sup> as essentially a single isomer (97:3 dr, 91%). Formation of the PMB ether of aldol adduct **10** [PMBTCA, cat. Sc(OTf)<sub>3</sub>] was followed by cleavage of the auxiliary under standard conditions<sup>9b</sup> to deliver aldehyde **11** in 72% yield. Corey–Fuchs<sup>13</sup> homologation of **11** to the vinyl dibromide then proceeded smoothly (98%) to install the latent terminal alkyne moiety. Finally, a Wacker oxidation<sup>14</sup> provided the required methyl ketone **4** (41% from **8**).

Efficient access to the C<sub>1</sub>–C<sub>9</sub> subunit **5**, containing the *trans*-disubstituted tetrahydropyran, was achieved in four steps from the known<sup>15</sup> dihydropyranone **12** (Scheme 2). Luche reduction of **12**, followed by acetylation, gave the Ferrier rearrangement substrate **13** cleanly (94%). Following previous work within our group,<sup>16</sup> treatment of ac-



**Scheme 3** Aldol coupling of **4** and **5** followed by elaboration to alkyne **7**.

etate **13** with (*i*-PrO)<sub>2</sub>TiCl<sub>2</sub> and TBSOCH=CH<sub>2</sub> gave the 2,6-*trans*-dihydropyran **14** as a single isomer, which was followed by hydrogenation of the alkene to provide aldehyde **5**. The remaining C<sub>17</sub>–C<sub>21</sub> subunit **3** was accessed (73%, 3 steps) from the PMB ether **15** of (*S*)-glycidol (Scheme 2). This involved copper-promoted epoxide opening with allylmagnesium bromide followed by methyl ether formation and oxidative cleavage of the alkene using OsO<sub>4</sub>/NaIO<sub>4</sub> to deliver the aldehyde **3**.




**Scheme 4** Coupling of **7** and **3** followed by elaboration into tricyclic C<sub>1</sub>–C<sub>21</sub> subunit **2**.

With the various subunits in hand, we were now ready to tackle the fragment coupling steps. We began by exploring the aldol coupling of methyl ketone **4** with aldehyde **5**, involving the installation of the C<sub>9</sub> stereocentre (Scheme 3). Initially, treatment of aldehyde **5** with the dicyclohexylboron enolate of **4** (*c*-Hex<sub>2</sub>BCl, Et<sub>3</sub>N) led to moderate selectivity (3:1 dr) in favour of the expected<sup>6</sup> 1,5-*anti* adduct **16**. However, this substrate induction could be significantly enhanced through reagent control, employing the matched diisopinocampheylboron enolate of **4** [(–)-Ipc<sub>2</sub>BCl, Et<sub>3</sub>N], to deliver adduct **16** as essentially a single isomer (>97:3 dr) in 79% yield. The stereochemical information at C<sub>9</sub> could now be relayed to C<sub>11</sub> via an Evans–Saksena reduction.<sup>17</sup> Thus, treatment of β-hydroxy ketone **16** with Me<sub>4</sub>NBH(OAc)<sub>3</sub> in MeCN–

AcOH (3:1) gave the 1,3-*anti* diol **17** (95:5 dr, 92%). Completion of the C<sub>1</sub>–C<sub>16</sub> alkyne subunit **7** proceeded smoothly in 90% yield from diol **17** via *bis*-TBS ether formation (TBSOTf) and treatment with *n*-BuLi to reveal the terminal alkyne.


At this stage, the fully elaborated open-chain precursor **6** for spiroacetal formation could be generated (Scheme 4). Fragment union was achieved via lithiation of alkyne **7** using *n*-BuLi, followed by addition of aldehyde **3**, to give adduct **18**, as an epimeric mixture at C<sub>17</sub>. Lindlar hydrogenation of **18** followed by Dess–Martin oxidation gave the corresponding (*Z*)-enone **6** cleanly (77%, 3 steps). Gratiifyingly, treatment of **6** with DDQ in buffered CH<sub>2</sub>Cl<sub>2</sub> effected clean deprotection of the PMB ethers at C<sub>13</sub> and C<sub>21</sub> and led initially to the in situ formation of two spiroacetals that equilibrated to a single isomer **2**, which was isolated in 61% yield. The successful formation of the desired spiroacetal stereochemistry was readily confirmed by <sup>1</sup>H and <sup>13</sup>C NMR analysis.<sup>11</sup> A strong NOE enhancement between H<sub>13</sub> and H<sub>21ax</sub>, also observed in the natural product, confirmed that the C<sub>17</sub> acetal centre of **2** possessed the desired configuration. As shown in Figure 1, a close correlation between the <sup>1</sup>H NMR data for the synthetic subunit and spirastrellolide was observed within the C<sub>13</sub>–C<sub>20</sub> spiroacetal region. In contrast, comparison of the C<sub>3</sub>–C<sub>12</sub> region revealed substantial differences, which suggested to us that the preliminary structural assignment of spirastrellolide as **1**<sup>5</sup> was probably incorrect.



**Figure 1** <sup>1</sup>H NMR chemical shift comparison for the C<sub>1</sub>–C<sub>21</sub> subunit **2** with spirastrellolide methyl ester **22** (Figure 2).

Around this time, the Andersen group revised the structure of spirastrellolide to **19** (Figure 2).<sup>2</sup> This new structure features a *cis*-disubstituted tetrahydropyran (A ring) and a [6,6]-spiroacetal (BC rings), together with additional stereochemical assignments (cf. circled carbon atoms), within the southern hemisphere. Furthermore, the northern hemisphere region was subject to more radical structural revision, now featuring a [5,6,6]-*bis*-spiroacetal (DEF rings) appended with a chlorine atom. In support of this revised structure **19** for spirastrellolide, our subsequent studies have led to the synthesis of the C<sub>1</sub>–C<sub>25</sub> subunit **20**, incorporating the appropriate stereochemical changes at C<sub>7</sub>, C<sub>9</sub> and C<sub>11</sub>, along with the C<sub>26</sub>–C<sub>40</sub> subunit **21**.<sup>18</sup> Both fragments now show excellent agreement with the corresponding NMR data obtained for the natural product.<sup>19</sup>

In summary, we have completed a highly convergent synthesis of the C<sub>1</sub>–C<sub>21</sub> spiroacetal-containing fragment **2** based on the original structural assignment of spiras-



**Figure 2** Revised structural assignment of spirastrellolide<sup>2</sup> and synthetic fragments prepared.<sup>18</sup>

trellolide A (16% yield over the longest linear sequence of 14 steps). Key features include the use of asymmetric boron aldol reactions to configure several stereocentres, along with the mild and selective conditions employed for spiroacetalisation. In more recent efforts directed towards the total synthesis of spirastrellolide A (**19**), this preliminary work has already helped guide our strategy for the construction of the stereochemically revised C<sub>1</sub>–C<sub>25</sub> subunit **20**.

### Acknowledgment

We thank the EPSRC (EP/C541677/1), Homerton College, Cambridge (Research Fellowship to E.A.A.) and Merck for support, and Professor Raymond Andersen (University of British Columbia) for helpful discussions.

### References

- (1) Williams, D. E.; Roberge, M.; Van Soest, R.; Andersen, R. *J. Am. Chem. Soc.* **2003**, *125*, 5296.
- (2) Williams, D. E.; Lapawa, M.; Feng, X.; Tarling, T.; Roberge, M.; Andersen, R. *J. Org. Lett.* **2004**, *6*, 2607.
- (3) (a) Le, L. H.; Erlichman, C.; Pillon, L.; Thiessen, J. J.; Day, A.; Wainman, N.; Eisenhauer, E. A.; Moore, M. J. *Invest. New Drugs* **2004**, *22*, 159. (b) Honkanen, R. E.; Golden, T. *Curr. Med. Chem.* **2002**, *9*, 2055.
- (4) For reviews on the synthesis of marine macrolides, see: (a) Norcross, R. D.; Paterson, I. *Chem. Rev.* **1995**, *95*, 2041. (b) Paterson, I.; Yeung, K.-S. *Chem. Rev.* **2005**, *105*, in press.
- (5) In addition to the originally proposed structure by Professor Andersen, as reported in ref. 1, a preliminary stereochemical assignment was made by us for the C<sub>1</sub>–C<sub>11</sub> region.
- (6) (a) Paterson, I.; Gibson, K. R.; Oballa, R. M. *Tetrahedron Lett.* **1996**, *37*, 8585. (b) Paterson, I.; Collett, L. A. *Tetrahedron Lett.* **2001**, *42*, 1187.
- (7) (a) Evans, D. A.; Coleman, P. J.; Côté, B. *J. Org. Chem.* **1997**, *62*, 788. (b) Evans, D. A.; Côté, B.; Coleman, P. J.; Connell, B. T. *J. Am. Chem. Soc.* **2003**, *125*, 10893.
- (8) Cowden, C. J.; Paterson, I. *Organic Reactions*, Vol. 51; Paquette, L. A., Ed.; Wiley: New York, **1997**, 1–200.
- (9) (a) Paterson, I.; Wallace, D. J.; Velazquez, S. M. *Tetrahedron Lett.* **1994**, *35*, 9083. (b) Paterson, I.; Wallace, D. J.; Cowden, C. J. *Synthesis* **1998**, 639.
- (10) Crimmins, M. T.; Kirincich, M. T.; Wells, S. J.; Choy, A. L. *Synth. Commun.* **1998**, *28*, 3675.
- (11) All new compounds gave spectroscopic data in agreement with the assigned structures. Compound **2** had  $[\alpha]_D^{22} = +34.5$  (*c* 0.80, CHCl<sub>3</sub>); <sup>1</sup>H NMR (500 MHz, C<sub>6</sub>D<sub>6</sub>):  $\delta = 7.78$ – $7.83$  (m, 4 H, ArH),  $7.22$ – $7.29$  (m, 6 H, ArH),  $5.60$  (dd, *J* = 9.9, 2.4 Hz, 1 H, H<sub>15</sub>),  $5.51$  (dd, *J* = 9.9, 1.7 Hz, 1 H, H<sub>16</sub>),  $4.38$  (m, 1 H, H<sub>11</sub>),  $4.22$  (m, 1 H, H<sub>9</sub>),  $4.07$  (m, 1 H, H<sub>3</sub>),  $4.03$  (m, 1 H, H<sub>7</sub>),  $3.94$  (m, 1 H, H<sub>21eq.</sub>),  $3.88$  (m, 3 H, 2 × H<sub>1</sub>, H<sub>21ax.</sub>),  $3.81$  (m, 1 H, H<sub>13</sub>),  $3.15$  (m, 1 H, H<sub>20</sub>),  $3.10$  (s, 3 H, OMe),  $2.12$  (m, 1 H, H<sub>8</sub>),  $2.10$  (m, 1 H, H<sub>2</sub>),  $2.09$  (1H, m, H<sub>10</sub>),  $2.04$  (m, 1 H, H<sub>10</sub>),  $2.02$  (m, 1 H, H<sub>14</sub>),  $1.97$  (m, 1 H, H<sub>19ax.</sub>),  $1.93$  (m, 2 H, 2 × H<sub>12</sub>),  $1.84$  (m, 1 H, H<sub>18eq.</sub>, H<sub>19eq.</sub>),  $1.82$  (m, 1 H, H<sub>2</sub>),  $1.76$  (m, 1 H, H<sub>8</sub>),  $1.65$  (m, 1 H, H<sub>6eq.</sub>),  $1.58$  (m, 1 H, H<sub>4eq.</sub>),  $1.50$  (m, 1 H, H<sub>18ax.</sub>),  $1.49$  (m, 2 H, 2 × H<sub>5</sub>),  $1.36$  (m, 1 H, H<sub>6ax.</sub>),  $1.25$  (m, 1 H, H<sub>4ax.</sub>),  $1.19$  (s, 9 H, Si<sup>t</sup>Bu),  $1.05$  (s, 9 H, Si<sup>t</sup>Bu),  $1.03$  (s, 9 H, Si<sup>t</sup>Bu),  $0.80$  (d, *J* = 7.1 Hz, 3 H, Me<sub>14</sub>),  $0.26$  (s, 3 H, SiMe),  $0.28$  (s, 3 H, SiMe),  $0.24$  (s, 3 H, SiMe),  $0.20$  (s, 3 H, SiMe); <sup>13</sup>C NMR (125 MHz, C<sub>6</sub>D<sub>6</sub>):  $\delta = 135.8$ ,  $135.7$ ,  $134.2$ ,  $134.1$ ,  $134.0$ ,  $129.7$ ,  $129.4$ ,  $93.0$ ,  $74.9$ ,  $71.0$ ,  $68.4$ ,  $68.3$ ,  $67.7$ ,  $67.6$ ,  $63.7$ ,  $61.5$ ,  $55.7$ ,  $46.6$ ,  $43.0$ ,  $42.5$ ,  $36.3$ ,  $34.5$ ,  $34.3$ ,  $30.8$ ,  $29.8$ ,  $27.0$ ,  $26.1$ ,  $26.0$ ,  $25.3$ ,  $19.3$ ,  $18.8$ ,  $18.2$ ,  $18.1$ ,  $17.0$ ,  $-3.5$ ,  $-3.7$ ,  $-3.9$ ,  $-4.0$ ; HRMS (ES<sup>+</sup>): *m/z* [M + H]<sup>+</sup> calcd for C<sub>51</sub>H<sub>87</sub>O<sub>7</sub>Si<sub>3</sub>: 895.5754; found: 895.5752.
- (12) The configuration at C<sub>13</sub> was confirmed by <sup>1</sup>H NMR analysis using the Kakisawa–Mosher method: Ohtani, I.; Kusumi, T.; Kashman, Y.; Kakisawa, H. *J. Am. Chem. Soc.* **1991**, *113*, 4092.
- (13) Corey, E. J.; Fuchs, P. L. *Tetrahedron Lett.* **1972**, *13*, 3769.
- (14) Tsuji, J. *Synthesis* **1984**, 369.
- (15) (a) Smith, A. B.; Minbiole, K. P.; Verhoest, P. R.; Schelhaas, M. *J. Am. Chem. Soc.* **2001**, *123*, 10942. (b) Dihydropyranone **12** was conveniently accessed via a Jacobsen hetero-Diels–Alder reaction between Danishefsky's diene and TPSO(CH<sub>2</sub>)<sub>2</sub>CHO in 94% yield and 99% ee.
- (16) Paterson, I.; Smith, J. D.; Ward, R. A. *Tetrahedron* **1995**, *51*, 9413.
- (17) Evans, D. A.; Chapman, K. T.; Carreira, E. M. *J. Am. Chem. Soc.* **1988**, *110*, 3560.
- (18) (a) Paterson, I.; Anderson, E. A.; Dalby, S. M.; Loiseleur, O. *Org. Lett.* **2005**, *7*, 4121. (b) Paterson, I.; Anderson, E. A.; Dalby, S. M.; Loiseleur, O. *Org. Lett.* **2005**, *7*, 4125.
- (19) For other synthetic studies towards spirastrellolide, see: (a) Liu, J.; Hsung, R. P. *Org. Lett.* **2005**, *7*, 2273. (b) Paterson, I.; Anderson, E. A.; Dalby, S. M.; Loiseleur, O. *Abstracts of Papers 229th National Meeting of the American Chemical Society, San Diego*; ACS: Washington D.C., **2005**, ORGN-331. (c) Wang, C.; Forsyth, C. J. *Abstracts of Papers 229th National Meeting of the American Chemical Society, San Diego*; ACS: Washington D.C., **2005**, ORGN-414.